🇪🇺 rVSV∆G-ZEBOV-GP in European Union

EMA authorised rVSV∆G-ZEBOV-GP on 11 November 2019

Marketing authorisation

EMA — authorised 11 November 2019

  • Application: EMEA/H/C/004554
  • Marketing authorisation holder: Merck Sharp & Dohme B.V.
  • Local brand name: Ervebo
  • Indication: Ervebo is indicated for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus. The use of Ervebo should be in accordance with official recommendations.
  • Pathway: PRIME
  • Status: approved

Read official source →

Other Immunology / Infectious Disease approved in European Union

Frequently asked questions

Is rVSV∆G-ZEBOV-GP approved in European Union?

Yes. EMA authorised it on 11 November 2019.

Who is the marketing authorisation holder for rVSV∆G-ZEBOV-GP in European Union?

Merck Sharp & Dohme B.V. holds the EU marketing authorisation.